Patents by Inventor Richard L. Vandlen

Richard L. Vandlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170362318
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: January 13, 2017
    Publication date: December 21, 2017
    Inventors: Craig Crowley, Frederic J. De Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • Publication number: 20130017200
    Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.
    Type: Application
    Filed: December 3, 2010
    Publication date: January 17, 2013
    Applicant: Genentech, Inc.
    Inventors: Justin Scheer, Richard L. Vandlen
  • Patent number: 8226935
    Abstract: Chimeric heteromultimer adhesins that bind the ligand of natural heromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of the ErbB2 and ErbB3 and ErbB2 and ErbB4. The chimeric ErB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: July 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Patent number: 8163518
    Abstract: Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: April 24, 2012
    Assignee: Genetech, Inc.
    Inventors: David P. Arnott, Jennie Lill, Wendy N. Sandoval, Richard L. Vandlen
  • Publication number: 20110206658
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: October 12, 2010
    Publication date: August 25, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Juntula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • Publication number: 20110070243
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 24, 2011
    Inventors: CRAIG CROWLEY, FREDERIC J. DE SAUVAGE, DAN L. EATON, ALLEN EBENS, JR., KRISTI ELKINS, JO-ANNE S. HONGO, JAGATH REDDY JUNUTULA, ANDREW POLSON, SARAJANE ROSS, VICTORIA SMITH, RICHARD L. VANDLEN, BING ZHENG
  • Publication number: 20110042260
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: August 12, 2010
    Publication date: February 24, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Jo-Anne S. Hongo, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen
  • Publication number: 20100135957
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 3, 2010
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Patent number: 7659368
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Patent number: 7601827
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: October 13, 2009
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Publication number: 20090181014
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 16, 2009
    Applicant: Genentech, Inc.
    Inventors: Heidi S. Phillips, Yu-Ju G. Meng, Richard L. Vandlen
  • Publication number: 20090068178
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: January 31, 2008
    Publication date: March 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • Publication number: 20070259398
    Abstract: Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.
    Type: Application
    Filed: April 27, 2007
    Publication date: November 8, 2007
    Applicant: Genentech, Inc.
    Inventors: David P. Arnott, Jennie Lill, Wendy N. Sandoval, Richard L. Vandlen
  • Patent number: 6953842
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 11, 2005
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Publication number: 20040138417
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 15, 2004
    Applicant: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Patent number: 6696290
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: February 24, 2004
    Assignee: Genentech, Inc.
    Inventors: Vincent Daniel Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Publication number: 20030199020
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Application
    Filed: March 12, 1999
    Publication date: October 23, 2003
    Inventors: VINCENT DANIAL FITZPATRICK, MARK SLIWKOWSKI, RICHARD L. VANDLEN
  • Publication number: 20030023035
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Application
    Filed: December 17, 2001
    Publication date: January 30, 2003
    Applicant: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 6399746
    Abstract: Novel polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: June 4, 2002
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Publication number: 20020002276
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Application
    Filed: July 25, 2001
    Publication date: January 3, 2002
    Applicant: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen